LAB Quote, Financials, Valuation and Earnings

Intelligent Bio Solutions, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -269.38%. Standard BioTools, Inc.'s return on equity of -24.44% beat Intelligent Bio Solutions, Inc.'s return on equity of -255.54%.

Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 7.64%. On the other hand Intelligent Bio Solutions, Inc. has an analysts' consensus of -- which suggests that it could grow by 1632.1%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe Intelligent Bio Solutions, Inc. is more attractive than Standard BioTools, Inc..

Standard BioTools, Inc. has a beta of 1.236, which suggesting that the stock is 23.585% more volatile than S&P 500. In comparison Intelligent Bio Solutions, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. Intelligent Bio Solutions, Inc. pays out -- of its earnings as a dividend.

Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than Intelligent Bio Solutions, Inc. quarterly revenues of $1.1M. Standard BioTools, Inc.'s net income of -$31.7M is lower than Intelligent Bio Solutions, Inc.'s net income of -$3M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while Intelligent Bio Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 4.24x versus 1.38x for Intelligent Bio Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -25.94%. Standard BioTools, Inc.'s return on equity of -24.44% beat LENSAR, Inc.'s return on equity of -1013.45%.

Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 7.64%. On the other hand LENSAR, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 42.99%. Given that LENSAR, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe LENSAR, Inc. is more attractive than Standard BioTools, Inc..

Standard BioTools, Inc. has a beta of 1.236, which suggesting that the stock is 23.585% more volatile than S&P 500. In comparison LENSAR, Inc. has a beta of 0.665, suggesting its less volatile than the S&P 500 by 33.53%.

Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. LENSAR, Inc. pays out -- of its earnings as a dividend.

Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than LENSAR, Inc. quarterly revenues of $14.3M. Standard BioTools, Inc.'s net income of -$31.7M is lower than LENSAR, Inc.'s net income of -$3.7M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while LENSAR, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 4.24x versus 2.10x for LENSAR, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Movano, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -5036.25%. Standard BioTools, Inc.'s return on equity of -24.44% beat Movano, Inc.'s return on equity of -410.28%.

Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 7.64%. On the other hand Movano, Inc. has an analysts' consensus of $30.00 which suggests that it could grow by 2976.92%. Given that Movano, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe Movano, Inc. is more attractive than Standard BioTools, Inc..

Standard BioTools, Inc. has a beta of 1.236, which suggesting that the stock is 23.585% more volatile than S&P 500. In comparison Movano, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Movano, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. Movano, Inc. pays out -- of its earnings as a dividend.

Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than Movano, Inc. quarterly revenues of $80K. Standard BioTools, Inc.'s net income of -$31.7M is lower than Movano, Inc.'s net income of -$4M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while Movano, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 4.24x versus 14.76x for Movano, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NeuroPace, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -12.78%. Standard BioTools, Inc.'s return on equity of -24.44% beat NeuroPace, Inc.'s return on equity of -149.8%.

Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 7.64%. On the other hand NeuroPace, Inc. has an analysts' consensus of $17.13 which suggests that it could grow by 5.04%. Given that Standard BioTools, Inc. has higher upside potential than NeuroPace, Inc., analysts believe Standard BioTools, Inc. is more attractive than NeuroPace, Inc..

Standard BioTools, Inc. has a beta of 1.236, which suggesting that the stock is 23.585% more volatile than S&P 500. In comparison NeuroPace, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroPace, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. NeuroPace, Inc. pays out -- of its earnings as a dividend.

Standard BioTools, Inc. quarterly revenues are $19.6M, which are smaller than NeuroPace, Inc. quarterly revenues of $27.4M. Standard BioTools, Inc.'s net income of -$31.7M is lower than NeuroPace, Inc.'s net income of -$3.5M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while NeuroPace, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 4.24x versus 5.59x for NeuroPace, Inc.. Usually stocks with elevated PS ratios are considered overvalued.